At Sandoz, we discover new ways to improve and extend people’s lives. We pioneer novel approaches to help people around the world access high-quality medicine. In 2015, our products reached an estimated 520 million patients and our aspiration is to reach 1 billion people.
In addition to the global #1 ranking in biosimilars1 and generic antibiotics2, dermatology2 and transplantation medicines2, Sandoz holds leading global positions in areas ranging from generic cardiovascular, central nervous system (CNS), pain and ophthalmology to oncology, respiratory and hormonal therapeutics. Our broad portfolio is backed by a range of state-of-the-art technologies, formulations and devices, including prolonged-release and multiple-unit tablets, creams and gels, orodispersible films, transdermal patches, lyophilized products, implants and inhalers.
In the combined regions of North America, Europe, Japan and Australia